Topic: pharmaceutical contract manufacturing
Taiho, Otsuka and Chugai wins KRAS-focused licensing deals. Biocon Biologics nabs PE funding before planned IPO. Mark Alles joins Antengene's board.
PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.
French CDMO Delpharm is planning a big expansion with a $274 million deal to pick up five sites from financially struggling Famar.
After manufacturing issues led ADMA Biologics to pull its primary immune deficiency disease drug Bivigam from the market, it's won a new FDA approval.
With two-thirds of its customers in the U.S., Sterling Pharma Solutions decided to buy a facility there.
Belgium-based Masthercell Global says it will build out a commercial-scale cell and gene manufacturing facility in its home country.
Novartis has reupped with Recro Pharma's CMO for production of two drugs, plus other news.
Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, weeks after Lonza completed its $5.5 billion buyout of Capsugel.
Boehringer Ingelheim saw a significant rise in sales in the first half of the year, in part from a healthy jump in its contract manufacturing operations.
Albany-New York based AMRI has agreed to a buyout worth more than $920 million as the M&A market for contract manufacturers continues to run hot.